You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBenazepril
Accession NumberDB00542  (APRD00063)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionBenazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
Structure
Thumb
Synonyms
1H-1-Benzazepine-1-acetic acid, 3-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(r*,r*))-
Benazepril
Benazeprilum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenazeprilTablet10 mgOralAa Pharma Inc2007-05-15Not applicableCanada
BenazeprilTablet20 mgOralAa Pharma Inc2006-03-24Not applicableCanada
BenazeprilTablet5 mgOralAa Pharma Inc2007-05-15Not applicableCanada
LotensinTablet20 mg/1OralNovartis Pharmaceuticals Corporation1991-06-252016-02-01Us
LotensinTablet10 mg/1OralValidus Pharmaceuticals LLC1991-06-21Not applicableUs
LotensinTablet5 mg/1OralPhysicians Total Care, Inc.1996-12-30Not applicableUs
LotensinTablet20 mg/1OralValidus Pharmaceuticals LLC1991-06-21Not applicableUs
LotensinTablet10 mg/1OralPhysicians Total Care, Inc.2003-11-04Not applicableUs
LotensinTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.1991-06-25Not applicableUs
LotensinTablet40 mg/1OralValidus Pharmaceuticals LLC1991-06-21Not applicableUs
LotensinTablet20 mg/1OralPhysicians Total Care, Inc.1994-03-23Not applicableUs
LotensinTablet40 mg/1OralNovartis Pharmaceuticals Corporation1991-06-252016-01-01Us
LotensinTablet5 mg/1OralValidus Pharmaceuticals LLC1991-06-21Not applicableUs
LotensinTablet40 mg/1OralPhysicians Total Care, Inc.1999-02-24Not applicableUs
Lotensin 10mgTablet10 mgOralNovartis Pharmaceuticals Canada Inc1993-12-312012-09-11Canada
Lotensin 20mgTablet20 mgOralNovartis Pharmaceuticals Canada Inc1993-12-31Not applicableCanada
Lotensin 5mgTablet5 mgOralNovartis Pharmaceuticals Canada Inc1993-12-31Not applicableCanada
PMS-benazeprilTablet20 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-benazeprilTablet5 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-benazeprilTablet10 mgOralPharmascience IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BenazeprilTablet20 mg/1OralSTAT Rx USA LLC2010-02-02Not applicableUs
BenazeprilTablet, coated40 mg/1OralInternational Laboratories, Inc.2013-09-19Not applicableUs
Benazepril HClTablet10 mg/1OralNorthwind Pharmaceuticals2016-06-23Not applicableUs
Benazepril HydrochlorideTablet, coated5 mg/1OralPhysicians Total Care, Inc.2005-08-19Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralRanbaxy Pharmaceuticals Inc.2010-09-06Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralSolco healthcare U.S., LLC2014-01-01Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralPreferred Pharmaceuticals Inc.2016-01-11Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralREMEDYREPACK INC.2016-05-04Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralMedsource Pharmaceuticals2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralUnit Dose Services2010-09-06Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralBlenheim Pharmacal, Inc.2013-11-08Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralApotex Corp2006-04-21Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1Oralbryant ranch prepack2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralPreferred Pharmaceuticals, Inc2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralCardinal Health2004-05-21Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralA S Medication Solutions2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, coated5 mg/1OralTeva Pharmaceuticals USA Inc2004-02-11Not applicableUs
Benazepril HydrochlorideTablet5 mg/1OralMajor Pharmaceuticals2010-02-02Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralAv Pak2014-04-15Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralGolden State Medical Supply, Inc.2015-07-15Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralRebel Distributors Corp.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralRanbaxy Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralAmerican Health Packaging2014-05-27Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralAv Kare, Inc.2009-07-29Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2014-01-01Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralA S Medication Solutions2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralEon Labs, Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralPd Rx Pharmaceuticals, Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralPhysicians Total Care, Inc.2004-05-17Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralREMEDYREPACK INC.2015-06-15Not applicableUs
Benazepril HydrochlorideTablet5 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, coated5 mg/1OralSolco healthcare U.S., LLC2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralPreferred Pharmaceuticals, Inc.2015-03-25Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralREMEDYREPACK INC.2011-06-162016-10-20Us
Benazepril HydrochlorideTablet, coated5 mg/1OralPd Rx Pharmaceuticals, Inc.2011-06-24Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralStat Rx USA2009-10-27Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralRanbaxy Pharmaceuticals Inc.2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralAurobindo Pharma Limited2008-05-22Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralRebel Distributors Corp.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralInternational Laboratories, Inc.2014-02-01Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralREMEDYREPACK INC.2016-07-20Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralTeva Pharmaceuticals USA Inc2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralNorthwind Pharmaceuticals2014-05-30Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralBlenheim Pharmacal, Inc.2013-11-13Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralSt. Mary's Medical Park Pharmacy2015-06-16Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1Oralbryant ranch prepack2009-06-29Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralPreferred Pharmaceuticals, Inc2012-01-122016-10-13Us
Benazepril HydrochlorideTablet, film coated10 mg/1OralCardinal Health2004-05-21Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralA S Medication Solutions2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralUnit Dose Services2014-01-01Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralMajor Pharmaceuticals2010-02-02Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralAv Pak2014-04-15Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralApotex Corp2006-04-16Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralAidarex Pharmaceuticals LLC2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralRanbaxy Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralPreferred Pharmaceuticals, Inc2010-09-06Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralAv Kare, Inc.2009-07-29Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralSolco healthcare U.S., LLC2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-12Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralEon Labs, Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralPhysicians Total Care, Inc.2004-08-25Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril HydrochlorideTablet, coated10 mg/1OralProficient Rx LP2014-01-01Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralMylan Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet5 mg/1OralAv Pak2014-04-14Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralGolden State Medical Supply, Inc.2015-07-15Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralRebel Distributors Corp.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralRanbaxy Pharmaceuticals Inc.2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralAurobindo Pharma Limited2008-05-22Not applicableUs
Benazepril HydrochlorideTablet5 mg/1OralAv Kare, Inc.2009-07-29Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralInternational Laboratories, Inc.2014-02-01Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralProficient Rx LP2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralTeva Pharmaceuticals USA Inc2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-09-06Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralBlenheim Pharmacal, Inc.2013-11-14Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralSt Marys Medical Park Pharmacy2014-01-15Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1Oralbryant ranch prepack2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralNorthwind Pharmaceuticals, LLC2016-03-04Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralREMEDYREPACK INC.2015-06-15Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralA S Medication Solutions2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralMylan Institutional Inc.2004-05-21Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralA S Medication Solutions2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralUnit Dose Services2014-01-01Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralMajor Pharmaceuticals2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralUnit Dose Services2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralApotex Corp2006-04-16Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralAidarex Pharmaceuticals LLC2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralRanbaxy Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralSolco healthcare U.S., LLC2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-12Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralEon Labs, Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralPhysicians Total Care, Inc.2005-01-05Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril HydrochlorideTablet, coated5 mg/1OralProficient Rx LP2014-01-01Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralMylan Pharmaceuticals Inc.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralAv Pak2014-04-15Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralGolden State Medical Supply, Inc.2015-07-15Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralRebel Distributors Corp.2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralRanbaxy Pharmaceuticals Inc.2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralAurobindo Pharma Limited2008-05-22Not applicableUs
Benazepril HydrochlorideTablet10 mg/1OralAv Kare, Inc.2010-07-29Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, coated5 mg/1OralAvera Mc Kennan Hospital2015-01-01Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralTeva Pharmaceuticals USA Inc2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2011-09-29Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralInternational Laboratories, Inc.2009-03-01Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralTrigen Laboratories, Inc.2012-11-15Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralSt Marys Medical Park Pharmacy2014-01-15Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1Oralbryant ranch prepack2004-02-11Not applicableUs
Benazepril HydrochlorideTablet, film coated5 mg/1OralPreferred Pharmaceuticals Inc.2016-03-15Not applicableUs
Benazepril HydrochlorideTablet, coated20 mg/1OralPreferred Pharmaceuticals, Inc.2015-03-25Not applicableUs
Benazepril HydrochlorideTablet20 mg/1OralA S Medication Solutions2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralPreferred Pharmaceuticals, Inc2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralMylan Institutional Inc.2004-05-21Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralA S Medication Solutions2014-01-01Not applicableUs
Benazepril HydrochlorideTablet, coated40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-01-01Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralMajor Pharmaceuticals2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated10 mg/1OralUnit Dose Services2010-09-06Not applicableUs
Benazepril HydrochlorideTablet, film coated20 mg/1OralApotex Corp2006-04-21Not applicableUs
Benazepril HydrochlorideTablet40 mg/1OralAidarex Pharmaceuticals LLC2010-02-02Not applicableUs
Benazepril HydrochlorideTablet, film coated40 mg/1OralRanbaxy Pharmaceuticals Inc.2004-02-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BriemPierre Fabre (France)
CibacenNovartis (Belgium, Philippines, Switzerland, Turkey), Meda (Denmark, Germany, Greece, Ireland, Italy, Netherlands, Spain)
CibaceneMeda (France)
Brand mixtures
NameLabellerIngredients
AmlobenzRebel Distributors Corp
Amlodipine and Benazepril HydrochlorideTeva Pharmaceuticals USA Inc
Amlodipine Besylate and Benazepril HClAmerican Health Packaging
Amlodipine Besylate and Benazepril HydrochlorideActavis Pharma, Inc.
Benazepril Hydrochloride and HydrochlorothiazideMylan Pharmaceuticals Inc.
Lotensin HctValidus Pharmaceuticals LLC
LotrelNovartis Pharmaceuticals Corporation
Salts
Name/CASStructureProperties
Benazepril Hydrochloride
Thumb
  • InChI Key: VPSRQEHTHIMDQM-FKLPMGAJSA-N
  • Monoisotopic Mass: 460.176499755
  • Average Mass: 460.95
DBSALT000554
Categories
UNIIUDM7Q7QWP8
CAS number86541-75-5
WeightAverage: 424.4895
Monoisotopic: 424.199822016
Chemical FormulaC24H28N2O5
InChI KeyXPCFTKFZXHTYIP-PMACEKPBSA-N
InChI
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
IUPAC Name
2-[(3S)-3-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CCC2=CC=CC=C2N(CC(O)=O)C1=O
Pharmacology
IndicationFor the treatment of hypertension. It may be used alone or in combination with thiazide diuretics.
Structured Indications
PharmacodynamicsBenazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by estarases to its active Benazeprilat, is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.
Mechanism of actionBenazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Benazeprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.
TargetKindPharmacological actionActionsOrganismUniProt ID
Angiotensin-converting enzymeProteinyes
inhibitor
HumanP12821 details
Related Articles
AbsorptionPeak in plasma within 0.5-1.0 hours. The extent of absorption is at least 37% as determined by urinary recovery and is not significantly influenced by the presence of food in the GI tract.
Volume of distributionNot Available
Protein bindingbenazepril, 97%; benazeprilat, 95%
Metabolism

Cleavage of the ester group (primarily in the liver) converts benazepril to its active metabolite, benazeprilat. Benazepril and benazeprilat may be conjugated to glucuronic acid prior to urinary excretion.

SubstrateEnzymesProduct
Benazepril
Not Available
benazeprilatDetails
Route of eliminationBenazepril and benazeprilat are cleared predominantly by renal excretion in healthy subjects with normal renal function. Nonrenal (i.e., biliary) excretion accounts for approximately 11%-12% of benazeprilat excretion in healthy subjects.
Half life10-11 hours
Clearance
  • 0.35 L/hr/kg [pediatric hypertensive patients receiving multiple daily doses of Benazepril hydrochloride 0.1 – 0.5 mg/kg]
  • 0.13 L/hr/kg [healthy adults receiving a single dose of 10 mg]
ToxicityMost likely symptom of overdosage is severe hypotension. Most common adverse effects include headache, dizziness, fatigue, somnolence, postural dizziness, nausea, and cough.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Benazepril Metabolism PathwayDrug metabolismSMP00591
Benazepril Action PathwayDrug actionSMP00145
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Benazepril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Benazepril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Benazepril is combined with Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Benazepril is combined with Acetovanillone.Investigational
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Benazepril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Benazepril is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Benazepril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Benazepril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Benazepril.Approved
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Benazepril.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Benazepril.Approved, Illicit, Investigational
AlprenololBenazepril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanBenazepril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Benazepril.Experimental
AmifostineBenazepril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Benazepril is combined with Amiloride.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Benazepril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Benazepril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Benazepril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Benazepril is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Benazepril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Benazepril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Benazepril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Benazepril is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Benazepril is combined with Amyl Nitrite.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Benazepril is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Benazepril is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Benazepril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Benazepril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Benazepril.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Benazepril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Benazepril is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Benazepril is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Benazepril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Benazepril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Azapropazone.Withdrawn
AzathioprineBenazepril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Benazepril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benazepril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Benazepril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Benazepril.Experimental
BarbitalBarbital may increase the hypotensive activities of Benazepril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Benazepril.Approved
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Benazepril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Benazepril.Withdrawn
BenoxaprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Benoxaprofen.Withdrawn
BepridilBenazepril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Benazepril.Approved
BethanidineBethanidine may increase the hypotensive activities of Benazepril.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Benazepril is combined with Betulinic Acid.Investigational
BimatoprostBenazepril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Benazepril is combined with Bisoprolol.Approved
BoceprevirThe serum concentration of Benazepril can be decreased when it is combined with Boceprevir.Approved
BortezomibThe risk or severity of adverse effects can be increased when Benazepril is combined with Bortezomib.Approved, Investigational
BosentanBenazepril may increase the hypotensive activities of Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Benazepril is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Benazepril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Benazepril.Approved
BromfenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Bromfenac.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Benazepril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Benazepril is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Benazepril is combined with Bupivacaine.Approved, Investigational
BupranololBenazepril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Benazepril.Approved
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Benazepril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Benazepril.Approved
CandoxatrilBenazepril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Captopril.Approved
CarbamazepineThe metabolism of Benazepril can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Benazepril is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Benazepril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Benazepril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Benazepril is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Benazepril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Celecoxib.Approved, Investigational
CeliprololBenazepril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Benazepril.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Benazepril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Benazepril is combined with Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Benazepril.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Benazepril is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Benazepril.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Cilnidipine.Approved
CiprofloxacinBenazepril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Benazepril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Benazepril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Benazepril is combined with Clofarabine.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Benazepril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Clonidine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Benazepril is combined with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Benazepril is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Benazepril is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Benazepril.Approved
CryptenamineBenazepril may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe risk or severity of adverse effects can be increased when Benazepril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benazepril.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Benazepril.Approved, Investigational, Vet Approved
CyclothiazideBenazepril may increase the hypotensive activities of Cyclothiazide.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Benazepril is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Benazepril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Benazepril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Benazepril.Investigational
DebrisoquinBenazepril may increase the hypotensive activities of Debrisoquin.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Benazepril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Benazepril.Investigational
DeserpidineBenazepril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Benazepril is combined with Desflurane.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Benazepril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Dexmedetomidine.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Benazepril.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Diclofenamide.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Benazepril.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Benazepril.Approved
DiflunisalDiflunisal may decrease the antihypertensive activities of Benazepril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Benazepril.Approved
DihydralazineBenazepril may increase the hypotensive activities of Dihydralazine.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Benazepril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Benazepril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Benazepril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Benazepril is combined with Dipyridamole.Approved
DorzolamideBenazepril may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Benazepril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Benazepril is combined with Doxazosin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Benazepril.Approved
DrospirenoneBenazepril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Droxicam.Approved
DuloxetineBenazepril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Benazepril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Benazepril.Approved
E6201The risk or severity of adverse effects can be increased when Benazepril is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Benazepril is combined with Ebselen.Investigational
EfonidipineBenazepril may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Benazepril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Enalapril.Approved, Vet Approved
EnalaprilatBenazepril may increase the hypotensive activities of Enalaprilat.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Benazepril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Benazepril.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Benazepril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Benazepril.Approved
EpoprostenolBenazepril may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Benazepril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Benazepril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Benazepril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Benazepril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Benazepril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Benazepril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Benazepril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Benazepril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Benazepril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Benazepril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Benazepril is combined with Etanercept.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Benazepril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Benazepril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Benazepril is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Benazepril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Benazepril is combined with Evening primrose oil.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Benazepril.Approved
exisulindThe risk or severity of adverse effects can be increased when Benazepril is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Benazepril is combined with Fenbufen.Approved
FenoldopamBenazepril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Benazepril is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Benazepril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Benazepril is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Benazepril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Benazepril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Benazepril.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Benazepril is combined with Furosemide.Approved, Vet Approved
GarlicThe serum concentration of Benazepril can be decreased when it is combined with Garlic.Approved
GuanabenzBenazepril may increase the hypotensive activities of Guanabenz.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Benazepril.Approved
GuanethidineBenazepril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Benazepril is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Benazepril is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
HexamethoniumBenazepril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Benazepril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Benazepril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Benazepril is combined with HMPL-004.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Benazepril.Approved
HydralazineThe risk or severity of adverse effects can be increased when Benazepril is combined with Hydralazine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Benazepril.Approved, Vet Approved
HydroflumethiazideBenazepril may increase the hypotensive activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Benazepril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Benazepril.Approved
IloprostIloprost may increase the hypotensive activities of Benazepril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Imidapril.Investigational
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Benazepril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Indapamide.Approved
IndenololBenazepril may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Benazepril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Indoprofen.Withdrawn
IndoraminBenazepril may increase the hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Benazepril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Benazepril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Benazepril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Benazepril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Benazepril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Benazepril is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Benazepril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Benazepril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Kebuzone.Experimental
KetanserinBenazepril may increase the hypotensive activities of Ketanserin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Benazepril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Benazepril is combined with Labetalol.Approved
LacidipineBenazepril may increase the hypotensive activities of Lacidipine.Approved
Lanthanum carbonateThe serum concentration of Benazepril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostBenazepril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Benazepril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Benazepril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Benazepril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Benazepril is combined with Levobupivacaine.Approved
LevodopaBenazepril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Benazepril is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Benazepril.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Benazepril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Benazepril.Approved
LofexidineBenazepril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Benazepril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Benazepril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Lumiracoxib.Approved, Investigational
MacitentanBenazepril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Benazepril is combined with Magnesium salicylate.Approved
ManidipineBenazepril may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Benazepril is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Benazepril is combined with Masoprocol.Approved
MebanazineMebanazine may increase the hypotensive activities of Benazepril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Benazepril is combined with Mecamylamine.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Benazepril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Benazepril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Benazepril is combined with Metamizole.Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Benazepril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Benazepril.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Benazepril.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Benazepril is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Benazepril.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Benazepril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Benazepril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Benazepril is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Benazepril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Benazepril.Approved, Investigational
MetyrosineBenazepril may increase the hypotensive activities of Metyrosine.Approved
MibefradilBenazepril may increase the hypotensive activities of Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Benazepril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Benazepril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Benazepril.Approved
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Benazepril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Benazepril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Benazepril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Benazepril.Approved
MorphineThe risk or severity of adverse effects can be increased when Benazepril is combined with Morphine.Approved, Investigational
MoxonidineBenazepril may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Benazepril is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Benazepril is combined with Nadolol.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Benazepril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Benazepril is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Benazepril is combined with Naftifine.Approved
NaftopidilBenazepril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of adverse effects can be increased when Benazepril is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Benazepril is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Benazepril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Benazepril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Benazepril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Benazepril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Benazepril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Benazepril.Approved
NifedipineThe risk or severity of adverse effects can be increased when Benazepril is combined with Nifedipine.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Benazepril is combined with Niflumic Acid.Approved
NiguldipineBenazepril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineBenazepril may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Benazepril is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Benazepril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Benazepril.Approved
NitrendipineBenazepril may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Benazepril is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Benazepril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Benazepril is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Benazepril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Benazepril.Approved
ObinutuzumabBenazepril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Benazepril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Benazepril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Benazepril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Benazepril is combined with Olsalazine.Approved
OmapatrilatBenazepril may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Benazepril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Benazepril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Benazepril is combined with Oxaprozin.Approved
OxprenololBenazepril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Benazepril is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Benazepril is combined with Papaverine.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Benazepril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Benazepril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Benazepril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Benazepril.Approved, Vet Approved
PentoliniumBenazepril may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Benazepril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Perindopril.Approved
PethidineThe risk or severity of adverse effects can be increased when Benazepril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Benazepril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Benazepril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Benazepril.Approved
PhenoxybenzamineBenazepril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Benazepril.Withdrawn
PhentolamineBenazepril may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Benazepril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Benazepril.Approved
PinacidilBenazepril may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Benazepril is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Pipamperone.Approved
PiretanidePiretanide may increase the hypotensive activities of Benazepril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Benazepril is combined with Pirfenidone.Investigational
PirlindolePirlindole may increase the hypotensive activities of Benazepril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Benazepril.Withdrawn
PolythiazideBenazepril may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Benazepril is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Benazepril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Benazepril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Benazepril.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Benazepril is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Benazepril is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Benazepril is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Benazepril.Approved
PTC299The risk or severity of adverse effects can be increased when Benazepril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Benazepril is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Quinapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Benazepril.Approved
QuinineQuinine may increase the hypotensive activities of Benazepril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Benazepril.Approved
RasagilineRasagiline may increase the hypotensive activities of Benazepril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Benazepril is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Benazepril.Approved
RescinnamineBenazepril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Benazepril.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Benazepril is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Benazepril.Approved
RilmenidineBenazepril may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Benazepril.Approved
RisperidoneBenazepril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabBenazepril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Benazepril is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Benazepril is combined with Ropivacaine.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Benazepril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Benazepril is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Benazepril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Benazepril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Benazepril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Benazepril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Benazepril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Benazepril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Benazepril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Benazepril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Benazepril.Approved, Investigational, Vet Approved
SelexipagBenazepril may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe risk or severity of adverse effects can be increased when Benazepril is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Benazepril is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Benazepril.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Benazepril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Benazepril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Benazepril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Benazepril.Approved, Investigational
SitaxentanBenazepril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Benazepril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Benazepril is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Benazepril.Approved
SpiraprilBenazepril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Benazepril.Approved
SRT501The risk or severity of adverse effects can be increased when Benazepril is combined with SRT501.Investigational
St. John's WortThe metabolism of Benazepril can be increased when combined with St. John's Wort.Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Benazepril is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Benazepril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Benazepril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Suprofen.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Benazepril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Benazepril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Benazepril.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Benazepril is combined with Tamsulosin.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Benazepril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Benazepril.Approved, Investigational
TemocaprilBenazepril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Benazepril is combined with Temsirolimus.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Benazepril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Benazepril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Benazepril is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Benazepril is combined with Teriflunomide.Approved
TerlipressinBenazepril may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Benazepril is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Benazepril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Benazepril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Benazepril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Benazepril is combined with Thioridazine.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Benazepril.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Benazepril is combined with Tiaprofenic acid.Approved
TiboloneBenazepril may increase the hypotensive activities of Tibolone.Approved
TicrynafenBenazepril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Benazepril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Benazepril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Benazepril.Approved
TipranavirThe serum concentration of Benazepril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Benazepril.Approved
TolazolineBenazepril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Benazepril is combined with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Benazepril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Benazepril.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Benazepril.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Benazepril.Approved
TranilastThe risk or severity of adverse effects can be increased when Benazepril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Benazepril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Benazepril.Approved
TravoprostTravoprost may increase the hypotensive activities of Benazepril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Benazepril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Benazepril is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Benazepril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Benazepril.Approved
TrichlormethiazideBenazepril may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinBenazepril may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanBenazepril may increase the hypotensive activities of Trimethaphan.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Benazepril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Benazepril.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Benazepril is combined with Trisalicylate-choline.Approved
UdenafilUdenafil may increase the antihypertensive activities of Benazepril.Approved, Investigational
UnoprostoneBenazepril may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Benazepril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Benazepril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Benazepril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Benazepril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Benazepril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Benazepril.Approved, Investigational
VinpocetineBenazepril may increase the hypotensive activities of Vinpocetine.Investigational
XylometazolineBenazepril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Benazepril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Benazepril is combined with Zaltoprofen.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Benazepril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Benazepril is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Benazepril is combined with Zomepirac.Withdrawn
Food Interactions
  • Benazepril may decrease the excretion of potassium. Salt um may increase the risk of hyperkalemia. substitutes containing potassi
  • Food slows absorption without decreasing the quantity absorbed.
  • Herbs that may attenuate the antihypertensive effect of benazepril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of benazepril.
  • Take without regard to meals.
References
Synthesis Reference

Wei-Hong Tseng, “ASYMMETRIC SYNTHESIS OF A KEY INTERMEDIATE FOR MAKING BENAZEPRIL AND ANALOGUES THEREOF.” U.S. Patent US20020183515, issued December 05, 2002.

US20020183515
General References
  1. Chan KK, Buch A, Glazer RD, John VA, Barr WH: Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. Pharm Res. 1994 Mar;11(3):432-7. [PubMed:8008712 ]
  2. De Feo P, Torlone E, Perriello G, Fanelli C, Epifano L, Di Vincenzo A, Modarelli F, Motolese M, Brunetti P, Bolli GB: Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension. Diabete Metab. 1992 Jul-Aug;18(4):283-8. [PubMed:1459316 ]
  3. Gengo FM, Brady E: The pharmacokinetics of benazepril relative to other ACE inhibitors. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV44-50; discussion IV51-5. [PubMed:1893642 ]
  4. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW: Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006 Jan 12;354(2):131-40. [PubMed:16407508 ]
  5. Ishimitsu T, Akashiba A, Kameda T, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H: Benazepril slows progression of renal dysfunction in patients with non-diabetic renal disease. Nephrology (Carlton). 2007 Jun;12(3):294-8. [PubMed:17498126 ]
  6. MacNab M, Mallows S: Safety profile of benazepril in essential hypertension. Clin Cardiol. 1991 Aug;14(8 Suppl 4):IV33-7; discussion IV51-5. [PubMed:1893640 ]
  7. Szekacs B, Vajo Z, Dachman W: Effect of ACE inhibition by benazepril, enalapril and captopril on chronic and post exercise proteinuria. Acta Physiol Hung. 1996;84(4):361-7. [PubMed:9328608 ]
External Links
ATC CodesC09AA07C09BA07
AHFS Codes
  • 24:32.04
PDB Entries
FDA labelDownload (237 KB)
MSDSDownload (57.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5732
Blood Brain Barrier-0.7082
Caco-2 permeable-0.7279
P-glycoprotein substrateSubstrate0.8466
P-glycoprotein inhibitor IInhibitor0.7426
P-glycoprotein inhibitor IINon-inhibitor0.7565
Renal organic cation transporterNon-inhibitor0.8239
CYP450 2C9 substrateNon-substrate0.7518
CYP450 2D6 substrateNon-substrate0.8563
CYP450 3A4 substrateSubstrate0.5632
CYP450 1A2 substrateNon-inhibitor0.8232
CYP450 2C9 inhibitorNon-inhibitor0.6875
CYP450 2D6 inhibitorNon-inhibitor0.8266
CYP450 2C19 inhibitorInhibitor0.5461
CYP450 3A4 inhibitorInhibitor0.5425
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6038
Ames testNon AMES toxic0.8377
CarcinogenicityNon-carcinogens0.9435
BiodegradationNot ready biodegradable0.9713
Rat acute toxicity2.2082 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9787
hERG inhibition (predictor II)Inhibitor0.6696
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Biokey inc
  • Genpharm inc
  • Huahai us inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc florida
  • Zydus pharmaceuticals usa inc
  • Novartis pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral10 mg/1
TabletOral40 mg/1
TabletOral5 mg/1
Tablet, coatedOral10 mg/1
Tablet, coatedOral20 mg/1
Tablet, coatedOral40 mg/1
Tablet, coatedOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
Tablet, film coatedOral5 mg/1
Tablet, coatedOral
Tablet, film coatedOral
TabletOral20 mg/1
TabletOral20 mg
TabletOral5 mg
TabletOral
CapsuleOral
Prices
Unit descriptionCostUnit
Lotensin 20 mg tablet2.08USD tablet
Lotensin 10 mg tablet2.0USD tablet
Lotensin 40 mg tablet2.0USD tablet
Lotensin 5 mg tablet2.0USD tablet
Lotensin HCT 20-12.5 mg tablet1.97USD tablet
Lotensin HCT 10-12.5 mg tablet1.95USD tablet
Lotensin HCT 20-25 mg tablet1.94USD tablet
Lotensin hct 10-12.5 tablet1.9USD tablet
Lotensin hct 20-12.5 tablet1.9USD tablet
Lotensin hct 20-25 tablet1.9USD tablet
Lotensin hct 5-6.25 tablet1.9USD tablet
Lotensin HCT 5-6.25 mg tablet1.31USD tablet
Lotensin 20 mg Tablet1.14USD tablet
Benazepril hcl 10 mg tablet1.07USD tablet
Benazepril hcl 20 mg tablet1.07USD tablet
Benazepril hcl 40 mg tablet1.07USD tablet
Benazepril hcl 5 mg tablet1.07USD tablet
Lotensin 10 mg Tablet0.99USD tablet
Lotensin 5 mg Tablet0.84USD tablet
Apo-Benazepril 20 mg Tablet0.79USD tablet
Apo-Benazepril 10 mg Tablet0.69USD tablet
Apo-Benazepril 5 mg Tablet0.58USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6162802 No1997-12-192017-12-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point148.5 °CPhysProp
water solubility2.229 mg/LNot Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0105 mg/mLALOGPS
logP1.14ALOGPS
logP1.54ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.53ChemAxon
pKa (Strongest Basic)5.36ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.23 m3·mol-1ChemAxon
Polarizability44.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Benzazepine
  • Phenylpropylamine
  • Aralkylamine
  • Fatty acid ester
  • Azepine
  • Fatty acyl
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein complex binding
Specific Function:
Catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine.
Gene Name:
MTHFR
Uniprot ID:
P42898
Molecular Weight:
74595.895 Da
References
  1. Jiang S, Yu Y, Venners SA, Zhang Y, Xing H, Wang X, Xu X: Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7. doi: 10.1038/jhh.2010.50. Epub 2010 May 6. [PubMed:20445573 ]
  2. Jiang S, Hsu YH, Niu T, Xu X, Xing H, Chen C, Wang X, Zhang Y, Peng S, Xu X: A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients--a family-based association study. Clin Exp Hypertens. 2005 Aug;27(6):509-21. [PubMed:16081343 ]
  3. Jiang S, Hsu YH, Xu X, Xing H, Chen C, Niu T, Zhang Y, Peng S, Xu X: The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with the level of decrease on diastolic blood pressure in essential hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res. 2004;113(6):361-9. [PubMed:15226090 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:41